mProX™ Human SIGLEC14 Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1

Target Classification

Immune Checkpoint Cell Lines

Gene ID

Human:100049587

UniProt ID

Human:Q08ET2

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

SIGLEC14 has been found to play a role in cellular and inflammatory immune responses to mumps vaccination. Genetic variants in the SIGLEC5/SIGLEC14 genes have been associated with decreased levels of mumps-specific cytokine production, specifically IL-1Œ≤ and TNFŒ±. This suggests that SNPs in the SIGLEC5/SIGLEC14 genes may influence the immune response to mumps vaccination. Additionally, SIGLEC14 has been identified as a receptor that recognizes carbon nanotubes, leading to inflammation. The binding of carbon nanotubes to SIGLEC14 triggers a proinflammatory response mediated by spleen tyrosine kinase (Syk) and the secretion of interleukin-1Œ≤. In an in vitro model of breast cancer, tamoxifen has been shown to modulate the immune landscape of the tumor microenvironment through the paired Siglec-5/14 checkpoint. Tamoxifen-induced alterations in the immune activity of breast cancer cells involve changes in the expression of SIGLEC5 and SIGLEC14 genes and their products, as well as the binding of Siglec-5 and Siglec-14 fusion proteins to breast cancer cells. These findings highlight the potential applications of SIGLEC14 in understanding and modulating immune responses in the context of vaccination and cancer therapy.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human SIGLEC14 Stable Cell Line (S01YF-1023-PY202). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Skyler Johnson (Verified Customer)

What is the association between SIGLEC14 and diseases like Alzheimer's? Nov 12 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Genetic variants associated with SIGLEC14 may impact the risk of Alzheimer's disease, indicating its potential role in neurodegenerative disorders. Nov 12 2020

chat Casey Williams (Verified Customer)

How does SIGLEC14 influence tuberculosis and vaccine response? Jul 20 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

SIGLEC14 expression is associated with clinical tuberculosis outcomes and BCG-induced immune responses, suggesting its role in infectious diseases and vaccine efficacy. Jul 20 2020

Published Data

Fig.1 The potential for cross-reactivity between Siglec-5 monoclonal antibodies and Siglec-14 is being investigated.

Cells transfected with Siglec-14/pIRES2-EGFP (dotted line), Siglec-5/pIRES2-EGFP (solid line), or pIRES2-EGFP (shaded) were probed with available monoclonal antibodies and subjected to analysis via flow cytometry. The populations that were positive for green fluorescent protein were gated and subsequently plotted. Both Siglec-5 and Siglec-14 were recognized by most monoclonal antibodies, with the exception of clone 194117.

Ref: Angata, Takashi, et al. "Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates." The FASEB Journal 20.12 (2006): 1964-1973.

Pubmed: 17012248

DOI: 10.1096/fj.06-5800com

Research Highlights

G Ovsyannikova, Inna. et al. "Genome-wide determinants of cellular immune responses to mumps vaccine." Vaccine, 2023.
The authors of this study have previously examined the role of genetic variations in certain candidate genes in influencing differences in antibody responses to mumps vaccination among individuals. Building on this previous research, they conducted a genome-wide association study (GWAS) to identify potential genetic variants that may impact cellular immune responses to mumps vaccines. These findings have the potential to further our understanding of the complex factors that contribute to variations in vaccine efficacy.
G Ovsyannikova, Inna. et al. "Genome-wide determinants of cellular immune responses to mumps vaccine." Vaccine, 2023.
Pubmed: 37778899 DOI: 10.1016/j.vaccine.2023.09.001

K, Michelle; J, Christopher. "Carbon nanotubes activate inflammatory signalling through binding to Siglec-14." Nature nanotechnology, 2023.
This article is a commentary on a recent study by Yamaguchi et al. that showed how carbon nanotubes can trigger inflammation by binding to a receptor called Siglec-14 on immune cells. The authors discuss the implications of this finding for nanotoxicology and nanomedicine, as well as the potential role of Siglec-14 in other diseases such as COVID-19 and tuberculosis. They also suggest some strategies to reduce the inflammatory effects of carbon nanotubes by modifying their surface properties or blocking Siglec-14.
K, Michelle; J, Christopher. "Carbon nanotubes activate inflammatory signalling through binding to Siglec-14." Nature nanotechnology, 2023.
Pubmed: 37316701 DOI: 10.1038/s41565-023-01420-4